Novo Nordisk A/S is focusing on novel diabetes R&D as its blockbuster drug Ozempic faces emerging competition, even as Ozempic sales made up for the firm’s struggling obesity franchise during the second quarter.
While the Danish firm grapples with manufacturing issues for its highly in-demand obesity drug Wegovy (semaglutide injection 2.4mg), its older...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
